# HSEF v5.3 review: Mouth Taping and Obstructive Sleep Apnea > Sources: 62 primary reports; claims: 67; verified: 67; unverified: 0. Verification is bounded attribution. Access: 1 partial-body and 61 bounded abstract/status examinations. Literature cutoff: 2026-10-13; source examination UTC date: 2026-10-13. No complete-paper audit or blinded calibration claimed. > **Adversarial review:** Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-14. 3 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: **Approved as revised.** ## AT A GLANCE **Small selected mouth-taping pilots report lower apnea indices; controlled evidence for tape alone remains insufficient, and closing a compensatory oral airway can worsen airflow.** | Level | Confidence | Causal role | Momentum | Stability | Divergence | |---|---|---|---|---|---| | Γ — Mechanistically plausible, partial system support | Moderate | epiphenomenon | Mechanistic only | Stable | Contested | **Deciding experiment:** A preregistered randomized crossover of the exact tape product versus credible sham/usual breathing in adults with baseline mouth-breathing OSA, with multiple nights per phase, blinded PSG scoring, washout/order balance, predefined nasal and velopharyngeal strata, and complete intolerance/adverse-event capture. **Belief versus evidence:** The preregistered primary-subclaim rule selects SC2 Γ. Anatomical plausibility and uncontrolled positive clinical signals exist, but the exact tape-alone natural-sleep causal contrast is missing. The other three subclaims also return Γ, so the alternative aggregation rules do not change the nominal grade. CPAP-adjunct efficacy and wearable validation are retained as separate findings. **Best-supported rival:** Closure effects depend on baseline obstruction. PMID39361293 distinguishes a uniform closure-benefit model from anatomy-dependent bidirectional airflow. PMID40963295 establishes a different randomized CPAP-adjunct outcome; it cannot be substituted for the nominal. ## COMPETING MECHANISTIC MODELS **Rank 1: Closure effects depend on baseline obstruction (Γ).** Nasal and velopharyngeal obstruction can make oral breathing compensatory, with bidirectional closure effects. PMID39361293 identifies increased flow in moderate oral breathers but decreased flow in high oral breathers during sedated closure; PMID15738298 manipulates nasal obstruction. Sedated airflow is not proof of natural-sleep clinical safety or a validated selection algorithm. **Rank 2: Established airway treatments account for adjunct benefits (Ε).** Pressure assistance, mandibular advancement and targeted muscle stimulation improve selected sleep endpoints independently of tape-alone claims. PMID40963295 randomizes tape added to CPAP; PMID38780959 favors mandibular advancement over a bundled snoring approach; PMID37022679 randomizes targeted stimulation. These different interventions do not prove a unique mechanism or universal response; objective, subjective and adverse outcomes differ. **Rank 3: Tape-only nasal-breathing treatment (Γ).** Taping promotes nasal breathing and thereby reduces apnea burden. PMIDs 25450408 and 36141367 report positive before-after mild-OSA outcomes. Credible concurrent tape-only controls are absent; tolerance selection, nasal treatment and night-to-night variability limit the inference. **Rank 4: Measurement and expectation influence apparent improvement (Β).** Single-night variability and patient expectation contribute to apparent sleep benefit. PMID34904935 quantifies multinight AHI variability, and the tracker validation originals identify patient-level error. These observations do not establish that every taped improvement is an artifact or that specific physiological closure effects are unreal. The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations. ## FULL REVIEW ### Registered claim and scope Nocturnal mouth taping reduces obstructive sleep apnea severity in adult mouth breathers. The declared clinical causal proposition is represented by SC2. Target engagement, superiority, mechanism, generalization and benefit-harm companions are separately reported and do not substitute for this primary claim. Selection: position 9 in the registered editorial traffic-priority list; registration timestamp 2026-10-13T15:39:25.266647+00:00. Ranked topics are editorial priorities, not measured worldwide popularity or a preassigned verdict. Registered claim assessed against original sources; no independent blinded calibration is claimed. ### Evidence and causal interpretation Rubric fit: No dedicated clinical exercise, sleep-device or environmental toxicology rubric ships in the frozen framework. The nearest rubric is explicitly adapted to controlled intervention on the registered clinical phenotype, with all exact universal caps and ladder preserved; mechanistic proxy-only evidence retains its cap. Methodological device validation is descriptive, not a causal HSEF claim. Rubric 07 is adapted to an objective sleep-device intervention: credible randomized sham or order-controlled closure comparisons with scored PSG/HST outcomes can qualify; a hallucination-matched placebo is irrelevant. Neither a single before-after night nor sedated airflow is a controlled sustained tape-alone clinical outcome. The two direct pilot reports have meaningful physiological signals, but design matters. Huang 2015 enrolls thirty mild-OSA mouth breathers and reports lower PSG AHI and sleepiness during a porous patch. Lee 2022 reports a one-week AHI change in twenty tolerated users. The original Lee Methods reveal retrospective assembly, exclusion of intolerance and nasal medications in obstructed patients. These observations are useful trial leads and do not establish the randomized tape-alone clinical effect. Closing an oral route can help or hinder flow. Yang 2024 directly changes closure during drug-induced endoscopy and finds opposite effects across baseline oral-breathing levels. Natural-sleep palatal prolapse and nasal-obstruction studies explain why mouth breathing can compensate for obstruction. Sedation and short physiological maneuvers remain separate from sustained home treatment. The 2025 randomized crossover provides a genuine positive CPAP-adjunct adherence result. It must be presented as addition to effective pressure assistance. Mandibular devices, drug-plus-closure and bundled snoring treatments likewise retain their component and indication limits. A positive package cannot establish the isolated contribution of tape. The companion sleep-score literature is descriptive rather than causally graded. Many devices estimate sleep-wake timing reasonably, while wake specificity, staging and severe-OSA performance vary. Some EEG wearables perform considerably better. A group-average agreement or generic score is not interchangeable with an individually validated AHI or functional endpoint. ## HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3) ### Subclaim matrix and aggregation | Subclaim | Scope | Level | Decision | |---|---|---|---| | SC1 Mouth closure modifies airflow and upper-airway physiology during sleep. | Adults with baseline mouth breathing and measured obstruction; natural sleep distinguished from drug-induced sleep | Γ | Closure changes surface tension, airway geometry, leak and airflow in waking, sedated or assisted-ventilation settings. The direction depends on obstruction anatomy. These partial systems do not establish a clinically effective tape-only mechanism during natural sleep; the proxy inference remains Γ. | | SC2 Nocturnal mouth taping reduces the apnea-hypopnea index by at least 30 percent in adult mouth breathers with baseline obstructive sleep apnea. | Baseline AHI at least 5; mouth breathing assessed before intervention; prespecified scored sleep; baseline obstruction severity retained | Γ | Two mild-OSA tape or porous-patch pilots show approximately 35-47 percent median AHI improvement, but neither provides the credible concurrent control required for a positive clinical crossing. The 2022 Methods identify retrospective selection, tolerated taping and concurrent nasal treatment. Randomized CPAP-adjunct and bundled snoring results retain their own scopes. Γ reflects partial mechanistic support and an unproven tape-alone clinical effect, not proof that taping never helps. | | SC3 Taping alone improves daytime function and subjective sleep quality. | No concurrent CPAP, mandibular advancement or nasal treatment attributed to tape alone | Γ | A prospective porous-patch pilot reports less sleepiness and a randomized CPAP-adjunct trial reports better symptoms and adherence. The first is uncontrolled and the second includes effective positive pressure. Neither establishes sustained functional benefit attributable to tape alone, so Γ applies. | | SC4 Taping benefit generalizes safely across baseline obstruction and nasal patency. | Nasal patency, AHI and obstruction phenotype determined before outcomes; safety directly measured | Γ | Airflow can worsen with mouth closure in high oral-breathing or velopharyngeal-obstructed patients. Chinstrap-assisted ventilation can also increase snoring or disturbance. Positive mild-OSA findings excluded several baseline problems and tape intolerance. This does not establish safe full-context generalization. Measurement studies separately show device- and disorder-specific accuracy; they are descriptive and do not earn clinical causal crossings. | Preregistered aggregation: primary-subclaim. The preregistered primary-subclaim rule selects SC2 Γ. Anatomical plausibility and uncontrolled positive clinical signals exist, but the exact tape-alone natural-sleep causal contrast is missing. The other three subclaims also return Γ, so the alternative aggregation rules do not change the nominal grade. CPAP-adjunct efficacy and wearable validation are retained as separate findings. Sensitivities: weakest-link Γ; primary-subclaim Γ; scope-matched Γ. ### Decisive-perturbation inventory and causal tally [2] Randomized primary-snoring study compares mandibular advancement with a nasal, positional and mouth-taping package; partner-rated response favors mandibular advancement. Participants lacked OSA and the bundle does not isolate taping; 42 of 50 dyads completed and adverse-event withdrawals occurred in both groups. [3] Twenty mild-OSA mouth breathers have lower median home-test AHI after one week of tolerated taping, from 8.3 to 4.7 events per hour. Uncontrolled before-after order, tolerance selection, single-night variability and outcome-defined snoring responders preclude a controlled clinical crossing or general safety claim. [5] Seventy-one participants undergo usual then taped home nights; about half lack ODI improvement and intermittent puffing correlates with severity and airway narrowing. Fixed night order and outcome-defined improved groups cannot identify causal responders prospectively or demonstrate controlled AHI benefit. [7] Random-order nights in 15 CPAP users show a chinstrap reduces mouth leak and arousals while increasing snoring time. Chinstrap is not tape alone; residual disturbance remains high and worsening respiratory disturbance in rare cases limits blanket safety claims. [8] Alternating-breath closure during drug-induced sleep endoscopy in 54 analyzed patients improves flow in moderate oral breathers but worsens it in high oral breathers and velopharyngeal obstruction. Sedated flow is not natural-sleep AHI or a tape trial; twelve excluded baseline-flow recordings and obstruction-dependent effects limit generalization. [58] Thirty mild-OSA open-mouth breathers have lower median PSG AHI and sleepiness during porous-patch use than baseline. Uncontrolled before-during assessment and a distinct patch formulation do not establish a credible controlled taping effect or necessity of the anatomical mediator. [59] Randomized crossover in 62 CPAP-treated OSA patients shows more device usage and improved symptom measures when tape is added, with adverse effects reported. The positive controlled result is CPAP adjunct adherence, not tape-alone AHI reduction; actual full-body safety details were not accessed here. [60] Random-order nasal-antagonist trial in ten OSA patients finds no systematic whole-cohort AHI change; the nasal-only closure-plus-drug arm is not superior. Drug and closure are bundled, baseline physiologic selection limits scope, and positive unrestricted-drug subgroup results do not establish tape efficacy. [61] Randomized mask-interface comparison in 29 CPAP users finds no significant objective difference between nasal mask alone and nasal mask with an oral shield. An oral shield is a CPAP adjunct, not tape alone; lack of significance is not proof of equivalence or no effect at all. Tally: 0 positive qualifying study units across scoped subclaims; 22 screened discriminating contrast units. These are not independent causal lines or proof of full-claim necessity/sufficiency. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. Direct tape-alone positive support is uncontrolled. No wearable validation earns a treatment crossing. Pivotal adverse or null contrasts are discriminators, not positive efficacy. An attached erratum does not add a reference. No positive field-valid crossing was verified for the registered causal scope in this bounded audit. Pivotal null or negative tests remain informative; their implications depend on comparator quality, target engagement, power and the registered scope. ### Cap audit, precedence and Β/Γ/Δ boundary A physiological perturbation crosses only the experimental question it tests. Waking or sedated airflow and controlled CPAP-adjunct results do not cross the registered tape-alone natural-sleep clinical boundary. Literal proxy and uncontrolled-class caps bind those offered inferences, while genuinely positive alternative treatments retain their clinical scope. Universal six-cap audit: All six universal caps were considered: cell-only inference, unperturbed association, ectopic expression, biomarker-only intervention, forced transfer/seeding, and inherited-to-sporadic scope transfer. Each binds its offered inference; complementary same-scope causal classes are assessed together rather than re-capped in isolation. Gamma hard-rule audit: The open-label rule caps the direct uncontrolled tape-only clinical support. Sedated/waking airway and leak changes are proxies for the registered natural-sleep clinical claim. Controlled CPAP-adjunct benefit does not override the tape-alone comparator gap. Wearable validation is descriptive and never a positive clinical perturbation. SC1 cap: “Biomarker change without functional/phenotypic change caps at Γ.” Closure changes surface tension, airway geometry, leak and airflow in waking, sedated or assisted-ventilation settings. The direction depends on obstruction anatomy. These partial systems do not establish a clinically effective tape-only mechanism during natural sleep; the proxy inference remains Γ. SC2 cap: “**Open-label rule.** Open-label, single-arm, retrospective, or naturalistic evidence alone. A positive open-label result never crosses Δ, however large.” Two mild-OSA tape or porous-patch pilots show approximately 35-47 percent median AHI improvement, but neither provides the credible concurrent control required for a positive clinical crossing. The 2022 Methods identify retrospective selection, tolerated taping and concurrent nasal treatment. Randomized CPAP-adjunct and bundled snoring results retain their own scopes. Γ reflects partial mechanistic support and an unproven tape-alone clinical effect, not proof that taping never helps. SC3 cap: “**Open-label rule.** Open-label, single-arm, retrospective, or naturalistic evidence alone. A positive open-label result never crosses Δ, however large.” A prospective porous-patch pilot reports less sleepiness and a randomized CPAP-adjunct trial reports better symptoms and adherence. The first is uncontrolled and the second includes effective positive pressure. Neither establishes sustained functional benefit attributable to tape alone, so Γ applies. SC1 field-valid definition: “at least one of: - Active comparator matched for acute subjective effect, blinding integrity measured and reported - Blinded on/off, staggered-onset, or randomized-withdrawal neuromodulation, reversible and within-subject - Mediator manipulation with the intervention intact: antagonist blockade of the acute experience with the drug still given, or dosing under general anaesthesia - Depletion or challenge experiment in humans whose outcome is symptom trajectory, not a biomarker - Psychotherapy component dismantling, or scaffold removal from a drug arm, with blinded assessors Rating-scale or biomarker change alone does NOT satisfy this threshold when the claim is functional, and statistical mediation alone never satisfies it.” Positive full-scope result: no. Closure changes surface tension, airway geometry, leak and airflow in waking, sedated or assisted-ventilation settings. The direction depends on obstruction anatomy. These partial systems do not establish a clinically effective tape-only mechanism during natural sleep; the proxy inference remains Γ. SC2 field-valid definition: “at least one of: - Active comparator matched for acute subjective effect, blinding integrity measured and reported - Blinded on/off, staggered-onset, or randomized-withdrawal neuromodulation, reversible and within-subject - Mediator manipulation with the intervention intact: antagonist blockade of the acute experience with the drug still given, or dosing under general anaesthesia - Depletion or challenge experiment in humans whose outcome is symptom trajectory, not a biomarker - Psychotherapy component dismantling, or scaffold removal from a drug arm, with blinded assessors Rating-scale or biomarker change alone does NOT satisfy this threshold when the claim is functional, and statistical mediation alone never satisfies it.” Positive full-scope result: no. Two mild-OSA tape or porous-patch pilots show approximately 35-47 percent median AHI improvement, but neither provides the credible concurrent control required for a positive clinical crossing. The 2022 Methods identify retrospective selection, tolerated taping and concurrent nasal treatment. Randomized CPAP-adjunct and bundled snoring results retain their own scopes. Γ reflects partial mechanistic support and an unproven tape-alone clinical effect, not proof that taping never helps. SC3 field-valid definition: “at least one of: - Active comparator matched for acute subjective effect, blinding integrity measured and reported - Blinded on/off, staggered-onset, or randomized-withdrawal neuromodulation, reversible and within-subject - Mediator manipulation with the intervention intact: antagonist blockade of the acute experience with the drug still given, or dosing under general anaesthesia - Depletion or challenge experiment in humans whose outcome is symptom trajectory, not a biomarker - Psychotherapy component dismantling, or scaffold removal from a drug arm, with blinded assessors Rating-scale or biomarker change alone does NOT satisfy this threshold when the claim is functional, and statistical mediation alone never satisfies it.” Positive full-scope result: no. A prospective porous-patch pilot reports less sleepiness and a randomized CPAP-adjunct trial reports better symptoms and adherence. The first is uncontrolled and the second includes effective positive pressure. Neither establishes sustained functional benefit attributable to tape alone, so Γ applies. SC4 field-valid definition: “at least one of: - Active comparator matched for acute subjective effect, blinding integrity measured and reported - Blinded on/off, staggered-onset, or randomized-withdrawal neuromodulation, reversible and within-subject - Mediator manipulation with the intervention intact: antagonist blockade of the acute experience with the drug still given, or dosing under general anaesthesia - Depletion or challenge experiment in humans whose outcome is symptom trajectory, not a biomarker - Psychotherapy component dismantling, or scaffold removal from a drug arm, with blinded assessors Rating-scale or biomarker change alone does NOT satisfy this threshold when the claim is functional, and statistical mediation alone never satisfies it.” Positive full-scope result: no. Airflow can worsen with mouth closure in high oral-breathing or velopharyngeal-obstructed patients. Chinstrap-assisted ventilation can also increase snoring or disturbance. Positive mild-OSA findings excluded several baseline problems and tape intolerance. This does not establish safe full-context generalization. Measurement studies separately show device- and disorder-specific accuracy; they are descriptive and do not earn clinical causal crossings. SC1 applied rubric adaptation (distinct from the unchanged literal criterion): The applied clinical sleep-device criterion is a credible controlled natural-sleep comparison of the exact closure intervention with objective apnea or functional outcomes. Waking/sedated airflow, assistive-pressure packages and device validation remain separate. SC2 applied rubric adaptation (distinct from the unchanged literal criterion): The applied clinical sleep-device criterion is a credible controlled natural-sleep comparison of the exact closure intervention with objective apnea or functional outcomes. Waking/sedated airflow, assistive-pressure packages and device validation remain separate. SC3 applied rubric adaptation (distinct from the unchanged literal criterion): The applied clinical sleep-device criterion is a credible controlled natural-sleep comparison of the exact closure intervention with objective apnea or functional outcomes. Waking/sedated airflow, assistive-pressure packages and device validation remain separate. SC4 applied rubric adaptation (distinct from the unchanged literal criterion): The applied clinical sleep-device criterion is a credible controlled natural-sleep comparison of the exact closure intervention with objective apnea or functional outcomes. Waking/sedated airflow, assistive-pressure packages and device validation remain separate. SC1 literal Γ hard rule: “**Functional-unblinding rule.** Inert-placebo trial of an intervention with unmistakable acute subjective effects — psychedelics, ketamine, entactogens, suprathreshold stimulation, ECT — with no blinding-integrity check reported. Such a trial did not control what it claims to control.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale. SC1 literal Γ hard rule: “**Mediation-by-correlation rule.** Candidate mediator correlated with outcome, never manipulated.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale. SC1 literal Γ hard rule: “**Open-label rule.** Open-label, single-arm, retrospective, or naturalistic evidence alone. A positive open-label result never crosses Δ, however large.” Triggered only for uncontrolled clinical-inference components; controlled physiological observations retain their tested experimental scope. SC1 literal Γ hard rule: “**Unblinded-rater rule.** Outcomes rated by clinicians who delivered the intervention or knew allocation.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale. SC1 literal Γ hard rule: “**Acute-pharmacodynamic rule.** Acute molecular, occupancy, or imaging change with no link to symptom trajectory.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale. SC1 literal Γ hard rule: “**Rodent-proxy rule.** Forced-swim, tail-suspension, sucrose-preference, or head-twitch alone; head-twitch is pharmacodynamic, not therapeutic.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale. SC2 literal Γ hard rule: “**Functional-unblinding rule.** Inert-placebo trial of an intervention with unmistakable acute subjective effects — psychedelics, ketamine, entactogens, suprathreshold stimulation, ECT — with no blinding-integrity check reported. Such a trial did not control what it claims to control.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale. SC2 literal Γ hard rule: “**Mediation-by-correlation rule.** Candidate mediator correlated with outcome, never manipulated.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale. SC2 literal Γ hard rule: “**Open-label rule.** Open-label, single-arm, retrospective, or naturalistic evidence alone. A positive open-label result never crosses Δ, however large.” Triggered for the direct uncontrolled clinical support class, with Γ ceiling; randomized adjuncts do not match tape-alone scope. SC2 literal Γ hard rule: “**Unblinded-rater rule.** Outcomes rated by clinicians who delivered the intervention or knew allocation.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale. SC2 literal Γ hard rule: “**Acute-pharmacodynamic rule.** Acute molecular, occupancy, or imaging change with no link to symptom trajectory.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale. SC2 literal Γ hard rule: “**Rodent-proxy rule.** Forced-swim, tail-suspension, sucrose-preference, or head-twitch alone; head-twitch is pharmacodynamic, not therapeutic.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale. SC3 literal Γ hard rule: “**Functional-unblinding rule.** Inert-placebo trial of an intervention with unmistakable acute subjective effects — psychedelics, ketamine, entactogens, suprathreshold stimulation, ECT — with no blinding-integrity check reported. Such a trial did not control what it claims to control.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale. SC3 literal Γ hard rule: “**Mediation-by-correlation rule.** Candidate mediator correlated with outcome, never manipulated.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale. SC3 literal Γ hard rule: “**Open-label rule.** Open-label, single-arm, retrospective, or naturalistic evidence alone. A positive open-label result never crosses Δ, however large.” Triggered for the direct uncontrolled clinical support class, with Γ ceiling; randomized adjuncts do not match tape-alone scope. SC3 literal Γ hard rule: “**Unblinded-rater rule.** Outcomes rated by clinicians who delivered the intervention or knew allocation.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale. SC3 literal Γ hard rule: “**Acute-pharmacodynamic rule.** Acute molecular, occupancy, or imaging change with no link to symptom trajectory.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale. SC3 literal Γ hard rule: “**Rodent-proxy rule.** Forced-swim, tail-suspension, sucrose-preference, or head-twitch alone; head-twitch is pharmacodynamic, not therapeutic.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale. SC4 literal Γ hard rule: “**Functional-unblinding rule.** Inert-placebo trial of an intervention with unmistakable acute subjective effects — psychedelics, ketamine, entactogens, suprathreshold stimulation, ECT — with no blinding-integrity check reported. Such a trial did not control what it claims to control.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale. SC4 literal Γ hard rule: “**Mediation-by-correlation rule.** Candidate mediator correlated with outcome, never manipulated.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale. SC4 literal Γ hard rule: “**Open-label rule.** Open-label, single-arm, retrospective, or naturalistic evidence alone. A positive open-label result never crosses Δ, however large.” Triggered only for uncontrolled clinical-inference components; controlled physiological observations retain their tested experimental scope. SC4 literal Γ hard rule: “**Unblinded-rater rule.** Outcomes rated by clinicians who delivered the intervention or knew allocation.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale. SC4 literal Γ hard rule: “**Acute-pharmacodynamic rule.** Acute molecular, occupancy, or imaging change with no link to symptom trajectory.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale. SC4 literal Γ hard rule: “**Rodent-proxy rule.** Forced-swim, tail-suspension, sucrose-preference, or head-twitch alone; head-twitch is pharmacodynamic, not therapeutic.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale. ### Upward threshold ladder SC1 Δ: “Requires a controlled human interventional study with a credible active comparator, or a mediator manipulation in humans, with a pre-registered primary outcome.” Satisfied: no. Dissociate closure from jaw advancement, nasal medication, pressure assistance and arousal while measuring natural-sleep obstruction and a prospective clinical outcome. SC2 Δ: “Requires a controlled human interventional study with a credible active comparator, or a mediator manipulation in humans, with a pre-registered primary outcome.” Satisfied: no. Conduct a preregistered randomized sham/order-controlled natural-sleep tape-only trial with multiple baseline and treatment nights, blinded scoring, all intolerance retained, and a prespecified AHI endpoint. SC3 Δ: “Requires a controlled human interventional study with a credible active comparator, or a mediator manipulation in humans, with a pre-registered primary outcome.” Satisfied: no. Show durable daytime function and symptom benefit with credible tape-alone control and independent assessors, rather than borrowing CPAP adherence or subjective before-after change. SC4 Δ: “Requires a controlled human interventional study with a credible active comparator, or a mediator manipulation in humans, with a pre-registered primary outcome.” Satisfied: no. Test baseline obstruction and nasal-patency strata prospectively, retain adverse changes and intolerance, and validate the measurement device for the actual patient and endpoint. Upper ladder: Randomized order, withdrawal/rechallenge and credible objective-scoring comparisons are feasible for a sleep device. The examined set does not provide replicated positive tape-only natural-sleep contrasts with mediator narrowing. Alternative airway therapies do not license an upper-ladder upgrade of tape alone. Independence: No two independent positive causal lines establish the exact tape-alone clinical claim. Repeated uncontrolled pilots are not independent mechanistic convergence; comparator interventions and measurement validations are separate questions. ### Falsification and pitfalls Scope fitted to the result. Outcome-defined snoring or ODI responders cannot redefine baseline scope. Therapeutic effect misread as mechanistic proof. CPAP-adjunct and mandibular packages do not establish tape-only mechanism. Confirmation by biomarker. Airway dimensions, sedated flow and wellness sleep scores do not replace controlled clinical endpoints. Causal-evidence tallies that do not survive an audit. Sixty-two reports include physiological comparators and measurement studies; they are not sixty-two tape trials. ### Adversarial steelman: above, then below One rung above (Δ): two independent mild-OSA pilots show substantial objective AHI reductions, nasal obstruction experiments make the biology plausible, and a newer randomized CPAP-adjunct trial reports genuine benefit. A controlled tape-alone clinical effect is scientifically credible. One rung below (Β): before-after AHI differences may be entirely due to variability, co-treatment or selection, and correlational oral breathing could follow obstruction. That is a credible critique of the clinical evidence. Δ is blocked by the missing credible tape-alone natural-sleep comparison and the explicit uncontrolled-study Γ rule. Β is rejected because direct physical closure perturbations supply partial system support beyond association. The assigned Γ preserves both plausible benefit and the unresolved clinical test. ### Final score, causal direction and M/S/D The preregistered primary-subclaim rule selects SC2 Γ. Anatomical plausibility and uncontrolled positive clinical signals exist, but the exact tape-alone natural-sleep causal contrast is missing. The other three subclaims also return Γ, so the alternative aggregation rules do not change the nominal grade. CPAP-adjunct efficacy and wearable validation are retained as separate findings. For the registered tape-only clinical benefit, no controlled dependency is demonstrated. The best-fitting mandatory role is epiphenomenon at step 2, meaning clinical causal direction remains unestablished; it does not deny that closure physically changes airflow. Momentum: Mechanistic only. Active controlled and mechanistic work exists in adjacent questions — the 2025 randomized CPAP-adjunct trial PMID40963295 and the drug-induced sleep endoscopy airflow studies — but no verified pending tape-alone trial addressing the boundary check was identified in this bounded search, so no named experiment could cross the next threshold. Momentum modifies no letter. Stability: Stable. No verified named pending tape-only result was identified. A prospectively registered multi-night sham/order-controlled trial could move the score upward or narrow it, but that is a proposed experiment rather than a scheduled trigger. Divergence: Contested. No manufactured field consensus or arithmetic gap. These dimensions do not change level or confidence. ## PROPOSED DECISIVE EXPERIMENTS A preregistered randomized crossover of the exact tape product versus credible sham/usual breathing in adults with baseline mouth-breathing OSA, with multiple nights per phase, blinded PSG scoring, washout/order balance, predefined nasal and velopharyngeal strata, and complete intolerance/adverse-event capture. Readout: Prespecified between-condition AHI reduction, hypoxic burden, daytime function and adverse breathing changes. Controls: Credible comparator, stable CPAP/nasal medication exclusion for tape-alone assessment, blinded scorers and order balance. Supporting: A clinically interpretable positive objective contrast replicated in baseline-defined strata with acceptable adverse outcomes. Falsifying: No controlled improvement, disappearance after order/multinight control, or worsened obstruction in prespecified strata. ## KNOWLEDGE GAPS A controlled tape-alone natural-sleep trial with adequate multi-night precision. A prospective baseline classifier that distinguishes compensatory oral breathing from modifiable mouth opening. Durable functional benefit beyond snoring or a single apnea index. Patient-level safety and intolerance rather than only tolerated-user efficacy. Endpoint- and device-specific validation of consumer tracking, independent of treatment efficacy. ## REVIEWER NOTES 62 primary reports were examined through bounded original abstract/status passages; one paper received selected Methods/Results checks at this stage. Most complete bodies and supplements were not audited. The direct 2022 Methods contradict any prospective-RCT characterization and identify co-treatment. The 2023 puffing abstract contains difficult subgroup percentages, and the 2020 endoscopy abstract has inconsistent significance wording; neither ambiguous number is promoted. Correction 38512282 remains attached to targeted-stimulation 37022679; unread correction details are not invented. Provider gap counts, meter percentages, radiographic mechanism certainty and anatomy-response claims are reconciled against originals. No independent blind calibration or scientific peer review is claimed. Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration. ## Consensus and original-source reconciliation The original is a thirty-person prospective before-during pilot. Its 35 percent median AHI change and sleepiness improvement are real reported findings, but no randomized concurrent control or anatomical-mediator necessity is established. [Original PMID25450408](https://pubmed.ncbi.nlm.nih.gov/25450408/). Consensus did not prominently retrieve Lee 2022 despite the explicit brief. Its actual Methods identify retrospective tolerated-user selection and treatment of nasal obstruction; the AHI change cannot be described as a controlled prospective tape-only trial. [Original PMID36141367](https://pubmed.ncbi.nlm.nih.gov/36141367/). The original abstract reports seventy-one participants and fixed usual-then-taped nights, with groups classified by measured ODI response. Provider wording using fifty-eight and a categorical adverse percentage is not adopted without matched body definitions. [Original PMID37032816](https://pubmed.ncbi.nlm.nih.gov/37032816/). The original defines drug-induced sleep endoscopy and alternating-breath manual closure, with worse flow in high oral breathers. This is mechanistic safety-relevant evidence, not a natural-sleep tape-only AHI trial; a provider omission is not absence of the study. [Original PMID39361293](https://pubmed.ncbi.nlm.nih.gov/39361293/). The sixty-two-person trial reports more CPAP usage with adjunct tape. This controlled finding is retained without converting it into tape-alone treatment efficacy. [Original PMID40963295](https://pubmed.ncbi.nlm.nih.gov/40963295/). The original finds high sleep sensitivity and limited wake specificity, mixed stages and worse disrupted-night performance. These are device-specific validation findings rather than a universal assertion that all wearable measurements are useless. [Original PMID33378539](https://pubmed.ncbi.nlm.nih.gov/33378539/). The original reports useful healthy-cohort agreement and device-specific stage biases. Blanket dismissal of all commercial stage estimates would ignore these distinctions. [Original PMID39460013](https://pubmed.ncbi.nlm.nih.gov/39460013/). Measured night-to-night AHI variability gives a concrete reason to require repeated baseline and treatment nights. The large purchaser sample does not itself prove that pilot improvements are artifacts. [Original PMID34904935](https://pubmed.ncbi.nlm.nih.gov/34904935/). Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades. ## Research timeline and gaps: Mouth Taping and Obstructive Sleep Apnea Selected publication milestones, not an exhaustive history or discovery priority claim. **1986 — Experimental upper-airway mechanics precede modern taping claims.** [Original PMID3093456](https://pubmed.ncbi.nlm.nih.gov/3093456/). **1993 — Waking CT reveals different regional responses to oral versus nasal breathing.** [Original PMID8131434](https://pubmed.ncbi.nlm.nih.gov/8131434/). **1999 — Random-order ventilation nights identify leak and assisted-support effects.** [Original PMID10624751](https://pubmed.ncbi.nlm.nih.gov/10624751/). **2004 — Chinstrap reduces assisted leak while increasing snoring in some users.** [Original PMID15165532](https://pubmed.ncbi.nlm.nih.gov/15165532/). **2005 — Controlled nasal treatment shows a separate upstream contribution to mouth breathing and OSA.** [Original PMID15738298](https://pubmed.ncbi.nlm.nih.gov/15738298/). **2015 — Thirty-person porous-patch pilot reports a positive uncontrolled mild-OSA signal.** [Original PMID25450408](https://pubmed.ncbi.nlm.nih.gov/25450408/). **2018 — Natural-sleep palatal prolapse provides a compensatory-route explanation.** [Original PMID29444914](https://pubmed.ncbi.nlm.nih.gov/29444914/). **2020 — Sedated closure anatomy is studied but does not isolate natural-sleep tape efficacy.** [Original PMID32162059](https://pubmed.ncbi.nlm.nih.gov/32162059/). **2022 — Large multinight dataset documents single-night diagnostic variability.** [Original PMID34904935](https://pubmed.ncbi.nlm.nih.gov/34904935/). **2022 — Retrospective mild-OSA tape pilot reports objective improvement with selection and co-treatment limits.** [Original PMID36141367](https://pubmed.ncbi.nlm.nih.gov/36141367/). **2023 — Fixed-order puffing study identifies many nonimproved outcomes.** [Original PMID37032816](https://pubmed.ncbi.nlm.nih.gov/37032816/). **2024 — Alternating-breath endoscopy finds bidirectional flow changes by baseline oral breathing.** [Original PMID39361293](https://pubmed.ncbi.nlm.nih.gov/39361293/). **2025 — Randomized CPAP-adjunct trial demonstrates a distinct adherence benefit.** [Original PMID40963295](https://pubmed.ncbi.nlm.nih.gov/40963295/). **2025 — Clinical ring validation exposes substantial individual errors despite acceptable group averages.** [Original PMID40108409](https://pubmed.ncbi.nlm.nih.gov/40108409/). ## Research gaps A controlled tape-alone natural-sleep trial with adequate multi-night precision. A prospective baseline classifier that distinguishes compensatory oral breathing from modifiable mouth opening. Durable functional benefit beyond snoring or a single apnea index. Patient-level safety and intolerance rather than only tolerated-user efficacy. Endpoint- and device-specific validation of consumer tracking, independent of treatment efficacy. ## Boundary experiment A preregistered randomized crossover of the exact tape product versus credible sham/usual breathing in adults with baseline mouth-breathing OSA, with multiple nights per phase, blinded PSG scoring, washout/order balance, predefined nasal and velopharyngeal strata, and complete intolerance/adverse-event capture. ## ADVERSARIAL REVIEW AND APPROVAL **Authoring model:** Sol 6.1 (HSEF v5.3 pipeline). **Adversarial reviewer:** Claude Opus 5.5 (Anthropic). **Date:** 2026-10-14. **Scope of checks.** All 62 REFERENCES PMIDs were re-verified against PubMed metadata: 62/62 resolve to the stated title, first author, journal and year, and 62/62 printed DOI strings match the PubMed DOI field exactly. No reference carries a retraction or expression of concern, and no reference has a consortium first author, so the dropped-collective-author rendering bug does not arise. Every reference carries a resolvable DOI, so the empty "DOI: ." rendering defect does not occur in this package. Twelve load-bearing numeric and directional claims were checked against the original abstracts: Huang 2015 (30 mild-OSA open-mouth breathers, median AHI 12.0 to 7.8 per hour, lower Epworth and snoring scores, prospective and uncontrolled); Lee 2022 (20 mild-OSA patients who tolerated sealing, median AHI 8.3 to 4.7 events per hour, a 47% change, with "responder" defined by a 50% snoring-index reduction); Yang 2024 (66 enrolled, 12 excluded for insufficient baseline airflow, 54 analysed, drug-induced sleep endoscopy with alternating-breath manual closure, flow increase overall but obstruction-dependent direction); Meksukree 2025 (randomized crossover, 62 CPAP-treated patients, 30 days per period, adherence and symptom gains, adverse effects reported); the 2023 mouth-puffing study (71 participants, fixed usual-then-taped night order, groups defined by measured ODI response, intermittent puffing higher in severe OSA and in the half whose ODI did not improve); Kuo 2004 (15 patients, random order, chinstrap lowers mouth leak and arousal index but raises snoring time and can rarely worsen the respiratory disturbance index); Osman 2024 (ten OSA patients, random order, no systematic AHI change and the nasal-only drug-plus-closure arm not superior); Foellner 2020 (29 CPAP users, no significant objective difference between nasal mask and nasal mask plus oral shield); Dieltjens 2024 (50 snoring dyads randomized, 42 completed, partner-rated response favouring mandibular advancement over the bundled package, withdrawals for adverse effects in both arms); Lechat 2022 (67 278 users, about 170 nights each, single-night misclassification of roughly 20-50%); and the two wearable-validation originals. All twelve were supported as stated. Scoring logic was re-derived against the frozen HSEF v5.3 SKILL.md and hsef-framework.md. | ID | Severity | Location | Original to corrected | Evidence | |---|---|---|---|---| | B1 | Minor | AT A GLANCE table, "Final score, causal direction and M/S/D", and scorecard `extended_scoring_MSD.momentum` | Momentum "Decisive work underway" to "Mechanistic only"; the artifact sentence rewritten accordingly | The framework defines "Decisive work underway" as "Someone is running an experiment that could cross the next threshold" and requires an artifact naming that work. The artifact given here names a published 2025 randomized trial in an adjacent indication (tape added to CPAP) and then states that no pending tape-alone trial was identified, which is the definition of "Mechanistic only" ("Active mechanistic work, but nothing addressing the boundary check"). The Stability entry independently records that no named pending tape-only result exists. Momentum modifies no letter, so the headline grade is unaffected. | | B2 | Editorial | 10 lines | Lost inter-word spaces restored: "PMIDs25450408 and36141367" to "PMIDs 25450408 and 36141367"; "Huang2015" to "Huang 2015"; "Lee2022" to "Lee 2022"; "Yang2024" to "Yang 2024"; "step2" to "step 2"; "Correction38512282 remains attached to targeted-stimulation37022679" to the spaced form; "Rubric07" to "Rubric 07"; "Oura Gen3 / Fitbit Sense2 / Apple8" to the spaced product names | Known upstream builder defect (round-2 defect list, item 4). Whitespace-only repair: with all whitespace removed the corrected file is character-identical to the Sol 6.1 original. | | B3 | Minor | scorecard `final_score.confidence_rationale` | "density, heterogeneous controls and incomplete access set the confidence" to a rationale resting on evidence density and reproducibility alone | The framework states that confidence reflects evidence density and reproducibility, and not the reviewer's belief or, by extension, the reviewer's access depth. The band was re-derived from density and reproducibility alone: the registered tape-alone question rests on two small uncontrolled pilots, every other controlled result tests a different intervention, and measured multinight variability is large. That is a Moderate band, so the band itself is unchanged and only its stated basis is corrected. Lead policy of 2026-10-14, two-step test, applied: access depth struck as a determinant, then the band re-derived from what remained. Step 2 leaves the band at Moderate because the review documents substantive evidence-quality and reproducibility concerns - the registered tape-alone question rests on two small uncontrolled pilots, every other controlled result tests a different intervention, and measured night-to-night apnea variability is large enough to unsettle single-night contrasts - and those are legitimate determinants; the High band's requirement of extensive independent replication across labs, models and assay modalities is not met. Access depth was not the only thing holding the band down, so no raise is warranted. | **Rejected findings (checked, no change).** 1. Headline letter and aggregation. preregistration.json declares rule "primary-subclaim" with primary "SC2" and a UTC timestamp matching the review text. All four subclaims return Gamma, so weakest-link, primary-subclaim and scope-matched coincide; there is no scope-matched misreading to correct here, and no subclaim sits at Epsilon. 2. Beta/Gamma boundary. Beta would require correlation without intervention science. Direct physical closure perturbations (drug-induced sleep endoscopy closure, chinstrap random-order nights, nasal-obstruction manipulation) supply partial experimental system support, while Delta requires a controlled human interventional study with a credible active comparator and a preregistered primary outcome, which the tape-alone literature does not provide. Gamma stands. 3. Causal role. "epiphenomenon" is derived at framework Step 2 for the registered tape-only clinical benefit and is explicitly not a denial that closure changes airflow. Correct as written. 4. Open-label cap. The Gamma ceiling applied to the two uncontrolled pilots is the literal rubric-07 open-label rule, correctly quoted, and the randomized CPAP-adjunct result is correctly held outside the tape-alone scope rather than used to lift the cap. 5. Causal tally of zero with 22 screened discriminating contrasts. The two positive tape pilots are uncontrolled before-after designs and the positive randomized results concern different interventions, so no positive qualifying unit for the registered scope is available. Defensible as written. 6. Reference 20 (PMID 28422345) prints 2019 while PubMed shows an April 2017 electronic date; the cited volume 28, issue 2 is the 2019 print issue. This is the standing e-pub versus issue-year convention, extended by one further year by that journal's publication backlog. Not an error. 7. Reference 62 (PMID 32162059) is reported as finding that mouth closure improves or at least does not worsen the airway, and the reviewer notes flag the abstract's inconsistent significance wording ("both p < 0.05" where the comparison is null). Flagging rather than adopting the number is the correct handling. 9. *"Best-supported rival" line.* Checked against the scorecard: `models_evaluated[0]` is rank 1 with `is_nominal` false and the review prints that rank-1 rival, so the renderer defect that prints the nominal model as its own rival does not occur here. The nominal is rank 3. 10. *Spliced-provenance artifacts.* This package carries no 9 October 2026 consensus-consistency block and no "earlier adversarial approval" clause, so neither the false-approval boilerplate nor the reviewer-notes contradiction reported elsewhere in this round can occur here. Verified by search. **Residual limitations.** One source was examined at partial-body depth and 61 at bounded abstract/status depth, so Methods-level characterisations (the retrospective assembly and concurrent nasal treatment in the 2022 taping study) rest on the package's own retrieval receipts. The correction attached to the targeted-stimulation trial (PMID 38512282) was not read. The scorecard and provenance header name the generating system "Codex"; this adversarial review does not alter package-level provenance strings. No independent blinded calibration is claimed. **Validator.** The frozen HSEF v5.3 validator was re-run on the revised scorecard and prose: 32 pass, 0 warn, 1 fail. The single failure is v5.lay_summary, which the validator itself marks "mandatory from v5.4" and which therefore does not apply to this v5.3 package. All v5.3 checks pass, including logic.aggregation, logic.cap_ceiling, logic.boundary_gamma, v5.ledger (62 sources / 67 claims), v5.provenance and quality.msd_default. **Approval:** Following adversarial review and the corrections listed above, the revised document is approved. - Claude Opus 5.5 (Anthropic), 2026-10-14. ## REFERENCES 1. Verma M, Seto-Poon M, Wheatley JR et al. Influence of breathing route on upper airway lining liquid surface tension in humans. The Journal of physiology. 2006. [PMID 16690717](https://pubmed.ncbi.nlm.nih.gov/16690717/). DOI: 10.1113/jphysiol.2005.102129. Access: abstract_metadata. Study: PMID16690717. 2. Ioerger P, Afshari A, Hentati F et al. Mandibular Advancement vs Combined Airway and Positional Therapy for Snoring: A Randomized Clinical Trial. JAMA otolaryngology-- head & neck surgery. 2024. [PMID 38780959](https://pubmed.ncbi.nlm.nih.gov/38780959/). DOI: 10.1001/jamaoto.2024.1035. Access: abstract_metadata. Study: PMID38780959. 3. Lee YC, Lu CT, Cheng WN et al. The Impact of Mouth-Taping in Mouth-Breathers with Mild Obstructive Sleep Apnea: A Preliminary Study. Healthcare (Basel, Switzerland). 2022. [PMID 36141367](https://pubmed.ncbi.nlm.nih.gov/36141367/). DOI: 10.3390/healthcare10091755. Access: full_text_partial. Study: PMID36141367. 4. Jau JY, Kuo TBJ, Li LPH et al. Mouth puffing phenomena of patients with obstructive sleep apnea when mouth-taped: device's efficacy confirmed with physical video observation. Sleep & breathing = Schlaf & Atmung. 2023. [PMID 35277783](https://pubmed.ncbi.nlm.nih.gov/35277783/). DOI: 10.1007/s11325-022-02588-0. Access: abstract_metadata. Study: PMID35277783. 5. Jau JY, Kuo TBJ, Li LPH et al. Mouth Puffing Phenomenon and Upper Airway Features May Be Used to Predict the Severity of Obstructive Sleep Apnea. Nature and science of sleep. 2023. [PMID 37032816](https://pubmed.ncbi.nlm.nih.gov/37032816/). DOI: 10.2147/NSS.S384387. Access: abstract_metadata. Study: PMID37032816. 6. Teschler H, Stampa J, Ragette R et al. Effect of mouth leak on effectiveness of nasal bilevel ventilatory assistance and sleep architecture. The European respiratory journal. 1999. [PMID 10624751](https://pubmed.ncbi.nlm.nih.gov/10624751/). DOI: 10.1183/09031936.99.14612519. Access: abstract_metadata. Study: PMID10624751. 7. Bachour A, Hurmerinta K, Maasilta P. Mouth closing device (chinstrap) reduces mouth leak during nasal CPAP. Sleep medicine. 2004. [PMID 15165532](https://pubmed.ncbi.nlm.nih.gov/15165532/). DOI: 10.1016/j.sleep.2003.11.004. Access: abstract_metadata. Study: PMID15165532. 8. Yang H, Huyett P, Wang TY et al. Mouth Closure and Airflow in Patients With Obstructive Sleep Apnea: A Nonrandomized Clinical Trial. JAMA otolaryngology-- head & neck surgery. 2024. [PMID 39361293](https://pubmed.ncbi.nlm.nih.gov/39361293/). DOI: 10.1001/jamaoto.2024.3319. Access: abstract_metadata. Study: PMID39361293. 9. Hsu YS, Ke YK, Kuo TBJ et al. Expiratory Velopharyngeal Obstruction: Sleep Endoscopy-Guided Treatment Strategies to Prevent Oral Breathing During Sleep. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2024. [PMID 39033356](https://pubmed.ncbi.nlm.nih.gov/39033356/). DOI: 10.1002/ohn.902. Access: abstract_metadata. Study: PMID39033356. 10. Tun Y, Hida W, Okabe S et al. Inspiratory effort sensation to added resistive loading in patients with obstructive sleep apnea. Chest. 2000. [PMID 11083683](https://pubmed.ncbi.nlm.nih.gov/11083683/). DOI: 10.1378/chest.118.5.1332. Access: abstract_metadata. Study: PMID11083683. 11. Kim HY, Jeong JI, Dhong HJ et al. Nasal obstruction and palate-tongue position on sleep-disordered breathing. Clinical and experimental otorhinolaryngology. 2013. [PMID 24353862](https://pubmed.ncbi.nlm.nih.gov/24353862/). DOI: 10.3342/ceo.2013.6.4.226. Access: abstract_metadata. Study: PMID24353862. 12. McLean HA, Urton AM, Driver HS et al. Effect of treating severe nasal obstruction on the severity of obstructive sleep apnoea. The European respiratory journal. 2005. [PMID 15738298](https://pubmed.ncbi.nlm.nih.gov/15738298/). DOI: 10.1183/09031936.05.00045004. Access: abstract_metadata. Study: PMID15738298. 13. Koutsourelakis I, Vagiakis E, Roussos C et al. Obstructive sleep apnoea and oral breathing in patients free of nasal obstruction. The European respiratory journal. 2006. [PMID 17005578](https://pubmed.ncbi.nlm.nih.gov/17005578/). DOI: 10.1183/09031936.00058406. Access: abstract_metadata. Study: PMID17005578. 14. Fitzpatrick MF, Driver HS, Chatha N et al. Partitioning of inhaled ventilation between the nasal and oral routes during sleep in normal subjects. Journal of applied physiology (Bethesda, Md. : 1985). 2003. [PMID 12433860](https://pubmed.ncbi.nlm.nih.gov/12433860/). DOI: 10.1152/japplphysiol.00658.2002. Access: abstract_metadata. Study: PMID12433860. 15. Okuyama M, Kato S, Sato S et al. Dynamic behaviour of the soft palate during nasal positive pressure ventilation under anaesthesia and paralysis: comparison between patients with and without obstructive sleep-disordered breathing. British journal of anaesthesia. 2018. [PMID 29397128](https://pubmed.ncbi.nlm.nih.gov/29397128/). DOI: 10.1016/j.bja.2017.11.016. Access: abstract_metadata. Study: PMID29397128. 16. Azarbarzin A, Sands SA, Marques M et al. Palatal prolapse as a signature of expiratory flow limitation and inspiratory palatal collapse in patients with obstructive sleep apnoea. The European respiratory journal. 2018. [PMID 29444914](https://pubmed.ncbi.nlm.nih.gov/29444914/). DOI: 10.1183/13993003.01419-2017. Access: abstract_metadata. Study: PMID29444914. 17. Burger CD, Stanson AW, Daniels BK et al. Fast-computed tomographic evaluation of the effect of route of breathing on upper airway size and function in normal men. Chest. 1993. [PMID 8131434](https://pubmed.ncbi.nlm.nih.gov/8131434/). DOI: 10.1378/chest.103.4.1032. Access: abstract_metadata. Study: PMID8131434. 18. Ruhle KH, Franke KJ, Domanski U et al. Quality of life, compliance, sleep and nasopharyngeal side effects during CPAP therapy with and without controlled heated humidification. Sleep & breathing = Schlaf & Atmung. 2011. [PMID 20503074](https://pubmed.ncbi.nlm.nih.gov/20503074/). DOI: 10.1007/s11325-010-0363-2. Access: abstract_metadata. Study: PMID20503074. 19. Bharadwaj R, Ravikumar A, Krishnaswamy NR. Evaluation of craniofacial morphology in patients with obstructive sleep apnea using lateral cephalometry and dynamic MRI. Indian journal of dental research : official publication of Indian Society for Dental Research. 2011. [PMID 22484864](https://pubmed.ncbi.nlm.nih.gov/22484864/). DOI: 10.4103/0970-9290.94566. Access: abstract_metadata. Study: PMID22484864. 20. Umemoto G, Toyoshima H, Yamaguchi Y et al. Therapeutic Efficacy of Twin-Block and Fixed Oral Appliances in Patients with Obstructive Sleep Apnea Syndrome. Journal of prosthodontics : official journal of the American College of Prosthodontists. 2019. [PMID 28422345](https://pubmed.ncbi.nlm.nih.gov/28422345/). DOI: 10.1111/jopr.12619. Access: abstract_metadata. Study: PMID28422345. 21. Ebato A, Suzuki H, Sakamaki T et al. Obstructive sleep apnea treatment with a twopiece mandibular advancement device with an elastic retention band in combination with orofacial myofunctional therapy: a case report. Sleep science (Sao Paulo, Brazil). 2019. [PMID 31105897](https://pubmed.ncbi.nlm.nih.gov/31105897/). DOI: 10.5935/1984-0063.20190050. Access: abstract_metadata. Study: PMID31105897. 22. Miller DJ, Sargent C, Roach GD. A Validation of Six Wearable Devices for Estimating Sleep, Heart Rate and Heart Rate Variability in Healthy Adults. Sensors (Basel, Switzerland). 2022. [PMID 36016077](https://pubmed.ncbi.nlm.nih.gov/36016077/). DOI: 10.3390/s22166317. Access: abstract_metadata. Study: PMID36016077. 23. Chinoy ED, Cuellar JA, Huwa KE et al. Performance of seven consumer sleep-tracking devices compared with polysomnography. Sleep. 2021. [PMID 33378539](https://pubmed.ncbi.nlm.nih.gov/33378539/). DOI: 10.1093/sleep/zsaa291. Access: abstract_metadata. Study: PMID33378539. 24. Robbins R, Weaver MD, Sullivan JP et al. Accuracy of Three Commercial Wearable Devices for Sleep Tracking in Healthy Adults. Sensors (Basel, Switzerland). 2024. [PMID 39460013](https://pubmed.ncbi.nlm.nih.gov/39460013/). DOI: 10.3390/s24206532. Access: abstract_metadata. Study: PMID39460013. 25. Lee T, Cho Y, Cha KS et al. Accuracy of 11 Wearable, Nearable, and Airable Consumer Sleep Trackers: Prospective Multicenter Validation Study. JMIR mHealth and uHealth. 2023. [PMID 37917155](https://pubmed.ncbi.nlm.nih.gov/37917155/). DOI: 10.2196/50983. Access: abstract_metadata. Study: PMID37917155. 26. Schyvens AM, Peters B, Van Oost NC et al. A performance validation of six commercial wrist-worn wearable sleep-tracking devices for sleep stage scoring compared to polysomnography. Sleep advances : a journal of the Sleep Research Society. 2025. [PMID 40303381](https://pubmed.ncbi.nlm.nih.gov/40303381/). DOI: 10.1093/sleepadvances/zpaf021. Access: abstract_metadata. Study: PMID40303381. 27. Song TA, Chowdhury SR, Malekzadeh M et al. AI-Driven sleep staging from actigraphy and heart rate. PloS one. 2023. [PMID 37195925](https://pubmed.ncbi.nlm.nih.gov/37195925/). DOI: 10.1371/journal.pone.0285703. Access: abstract_metadata. Study: PMID37195925. 28. Tondo P, Dell'Olio F, Lacedonia D et al. A consumer wearable device for tracking sleep respiratory events. Sleep & breathing = Schlaf & Atmung. 2023. [PMID 36378480](https://pubmed.ncbi.nlm.nih.gov/36378480/). DOI: 10.1007/s11325-022-02743-7. Access: abstract_metadata. Study: PMID36378480. 29. Guo J, Luo J, Xiao Y et al. Validity and clinical utility of a wrist-worn device against polysomnography. PloS one. 2025. [PMID 41026691](https://pubmed.ncbi.nlm.nih.gov/41026691/). DOI: 10.1371/journal.pone.0330774. Access: abstract_metadata. Study: PMID41026691. 30. Fonseca P, Ross M, Cerny A et al. A computationally efficient algorithm for wearable sleep staging in clinical populations. Scientific reports. 2023. [PMID 37280297](https://pubmed.ncbi.nlm.nih.gov/37280297/). DOI: 10.1038/s41598-023-36444-2. Access: abstract_metadata. Study: PMID37280297. 31. Lechat B, Naik G, Reynolds A et al. Multinight Prevalence, Variability, and Diagnostic Misclassification of Obstructive Sleep Apnea. American journal of respiratory and critical care medicine. 2022. [PMID 34904935](https://pubmed.ncbi.nlm.nih.gov/34904935/). DOI: 10.1164/rccm.202107-1761OC. Access: abstract_metadata. Study: PMID34904935. 32. Jung H, Kim D, Choi J et al. Validating a Consumer Smartwatch for Nocturnal Respiratory Rate Measurements in Sleep Monitoring. Sensors (Basel, Switzerland). 2023. [PMID 37766031](https://pubmed.ncbi.nlm.nih.gov/37766031/). DOI: 10.3390/s23187976. Access: abstract_metadata. Study: PMID37766031. 33. Kim K, Park DY, Song YJ et al. Consumer-grade sleep trackers are still not up to par compared to polysomnography. Sleep & breathing = Schlaf & Atmung. 2022. [PMID 34741243](https://pubmed.ncbi.nlm.nih.gov/34741243/). DOI: 10.1007/s11325-021-02493-y. Access: abstract_metadata. Study: PMID34741243. 34. de Zambotti M, Goldstone A, Claudatos S et al. A validation study of Fitbit Charge 2™ compared with polysomnography in adults. Chronobiology international. 2018. [PMID 29235907](https://pubmed.ncbi.nlm.nih.gov/29235907/). DOI: 10.1080/07420528.2017.1413578. Access: abstract_metadata. Study: PMID29235907. 35. Hafezi M, Montazeri N, Zhu K et al. Sleep Apnea Severity Estimation from Respiratory Related Movements Using Deep Learning. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference. 2019. [PMID 31946202](https://pubmed.ncbi.nlm.nih.gov/31946202/). DOI: 10.1109/EMBC.2019.8857524. Access: abstract_metadata. Study: PMID31946202. 36. Naik GR, Breen PP, Jayarathna T et al. Morphic Sensors for Respiratory Parameters Estimation: Validation against Overnight Polysomnography. Biosensors. 2023. [PMID 37504102](https://pubmed.ncbi.nlm.nih.gov/37504102/). DOI: 10.3390/bios13070703. Access: abstract_metadata. Study: PMID37504102. 37. Miller DJ, Lastella M, Scanlan AT et al. A validation study of the WHOOP strap against polysomnography to assess sleep. Journal of sports sciences. 2020. [PMID 32713257](https://pubmed.ncbi.nlm.nih.gov/32713257/). DOI: 10.1080/02640414.2020.1797448. Access: abstract_metadata. Study: PMID32713257. 38. Altini M, Kinnunen H. The Promise of Sleep: A Multi-Sensor Approach for Accurate Sleep Stage Detection Using the Oura Ring. Sensors (Basel, Switzerland). 2021. [PMID 34201861](https://pubmed.ncbi.nlm.nih.gov/34201861/). DOI: 10.3390/s21134302. Access: abstract_metadata. Study: PMID34201861. 39. Herberger S, Aurnhammer C, Bauerfeind S et al. Performance of wearable finger ring trackers for diagnostic sleep measurement in the clinical context. Scientific reports. 2025. [PMID 40108409](https://pubmed.ncbi.nlm.nih.gov/40108409/). DOI: 10.1038/s41598-025-93774-z. Access: abstract_metadata. Study: PMID40108409. 40. van der Aar JF, van Gilst MM, van den Ende DA et al. Optimizing wearable single-channel electroencephalography sleep staging in a heterogeneous sleep-disordered population using transfer learning. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2025. [PMID 39347545](https://pubmed.ncbi.nlm.nih.gov/39347545/). DOI: 10.5664/jcsm.11380. Access: abstract_metadata. Study: PMID39347545. 41. Van de Perck E, Dieltjens M, Vroegop AV et al. Mandibular advancement device therapy in patients with epiglottic collapse. Sleep & breathing = Schlaf & Atmung. 2022. [PMID 34993758](https://pubmed.ncbi.nlm.nih.gov/34993758/). DOI: 10.1007/s11325-021-02532-8. Access: abstract_metadata. Study: PMID34993758. 42. Nagano T, Hashimoto M, Izumi S et al. Effect of 10-minute oropharyngeal exercise on the apnoea-hypopnoea index. Scientific reports. 2024. [PMID 39562675](https://pubmed.ncbi.nlm.nih.gov/39562675/). DOI: 10.1038/s41598-024-79884-0. Access: abstract_metadata. Study: PMID39562675. 43. Kuna ST, Smickley J. Response of genioglossus muscle activity to nasal airway occlusion in normal sleeping adults. Journal of applied physiology (Bethesda, Md. : 1985). 1988. [PMID 3356654](https://pubmed.ncbi.nlm.nih.gov/3356654/). DOI: 10.1152/jappl.1988.64.1.347. Access: abstract_metadata. Study: PMID3356654. 44. Fouke JM, Teeter JP, Strohl KP. Pressure-volume behavior of the upper airway. Journal of applied physiology (Bethesda, Md. : 1985). 1986. [PMID 3093456](https://pubmed.ncbi.nlm.nih.gov/3093456/). DOI: 10.1152/jappl.1986.61.3.912. Access: abstract_metadata. Study: PMID3093456. 45. Minoura A, Ihara Y, Kato H et al. Relationships between Lip Seal Strength, Tongue Pressure, and Daytime Sleepiness in Japanese Workers: A Cross-Sectional Study. Clinics and practice. 2023. [PMID 37489417](https://pubmed.ncbi.nlm.nih.gov/37489417/). DOI: 10.3390/clinpract13040068. Access: abstract_metadata. Study: PMID37489417. 46. Zhu X, Wimms AJ, Benjafield AV. Assessment of the performance of nasal pillows at high CPAP pressures. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2013. [PMID 23997699](https://pubmed.ncbi.nlm.nih.gov/23997699/). DOI: 10.5664/jcsm.2984. Access: abstract_metadata. Study: PMID23997699. 47. Messineo L, Keasling C, Hughes B et al. The impact of V̇-Com on chinstrap usage and study completion rates during CPAP titration. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2025. [PMID 41025402](https://pubmed.ncbi.nlm.nih.gov/41025402/). DOI: 10.5664/jcsm.11900. Access: abstract_metadata. Study: PMID41025402. 48. Martinot JB, Le-Dong NN, Cuthbert V et al. The key role of the mandible in modulating airflow amplitude during sleep. Respiratory physiology & neurobiology. 2020. [PMID 32416331](https://pubmed.ncbi.nlm.nih.gov/32416331/). DOI: 10.1016/j.resp.2020.103447. Access: abstract_metadata. Study: PMID32416331. 49. Schwartz AR, Jacobowitz O, Eisele DW et al. Targeted Hypoglossal Nerve Stimulation for Patients With Obstructive Sleep Apnea: A Randomized Clinical Trial. JAMA otolaryngology-- head & neck surgery. 2023. [PMID 37022679](https://pubmed.ncbi.nlm.nih.gov/37022679/). DOI: 10.1001/jamaoto.2023.0161. Access: abstract_metadata. Study: THN_NCT02263859. 50. Op de Beeck S, Wellman A, Dieltjens M et al. Endotypic Mechanisms of Successful Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea. American journal of respiratory and critical care medicine. 2021. [PMID 32970962](https://pubmed.ncbi.nlm.nih.gov/32970962/). DOI: 10.1164/rccm.202006-2176OC. Access: abstract_metadata. Study: STAR_secondary_analysis_NCT01161420. 51. Lou B, Rusk S, Nygate YN et al. Association of hypoglossal nerve stimulator response with machine learning identified negative effort dependence patterns. Sleep & breathing = Schlaf & Atmung. 2023. [PMID 35622197](https://pubmed.ncbi.nlm.nih.gov/35622197/). DOI: 10.1007/s11325-022-02641-y. Access: abstract_metadata. Study: PMID35622197. 52. Singh G, Luthra N, Jain R et al. Comparison of nasal and face mask ventilation in anaesthetised obese adults: A randomised controlled study. Indian journal of anaesthesia. 2024. [PMID 38476539](https://pubmed.ncbi.nlm.nih.gov/38476539/). DOI: 10.4103/ija.ija_404_23. Access: abstract_metadata. Study: PMID38476539. 53. Berthon-Jones M. Feasibility of a self-setting CPAP machine. Sleep. 1993. [PMID 8177999](https://pubmed.ncbi.nlm.nih.gov/8177999/). DOI: 10.1093/sleep/16.suppl_8.s120. Access: abstract_metadata. Study: PMID8177999. 54. Guzman MA, Sgambati FP, Pho H et al. The Efficacy of Low-Level Continuous Positive Airway Pressure for the Treatment of Snoring. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2017. [PMID 28356182](https://pubmed.ncbi.nlm.nih.gov/28356182/). DOI: 10.5664/jcsm.6588. Access: abstract_metadata. Study: PMID28356182. 55. Sleeper G, Rashidi M, Strohl KP et al. Comparison of expiratory pressures generated by four different EPAP devices in a laboratory bench setting. Sleep medicine. 2022. [PMID 35613539](https://pubmed.ncbi.nlm.nih.gov/35613539/). DOI: 10.1016/j.sleep.2022.05.004. Access: abstract_metadata. Study: PMID35613539. 56. Tegelberg Å, Nohlert E, List T et al. Oral appliance influence on jaw function in obstructive sleep apnea. American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics. 2023. [PMID 37318425](https://pubmed.ncbi.nlm.nih.gov/37318425/). DOI: 10.1016/j.ajodo.2023.04.018. Access: abstract_metadata. Study: PMID37318425. 57. Schneiderman E, Schramm P, Hui J et al. Randomized Trial of 2 Self-Titrated Oral Appliances for Airway Management. Journal of dental research. 2021. [PMID 32942939](https://pubmed.ncbi.nlm.nih.gov/32942939/). DOI: 10.1177/0022034520956977. Access: abstract_metadata. Study: PMID32942939. 58. Huang TW, Young TH. Novel porous oral patches for patients with mild obstructive sleep apnea and mouth breathing: a pilot study. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2015. [PMID 25450408](https://pubmed.ncbi.nlm.nih.gov/25450408/). DOI: 10.1177/0194599814559383. Access: abstract_metadata. Study: PMID25450408. 59. Meksukree A, Pitipanyakul S, Laohavinij W et al. The role of mouth tape for CPAP use in patients with mouth breathing and OSA. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2025. [PMID 40963295](https://pubmed.ncbi.nlm.nih.gov/40963295/). DOI: 10.5664/jcsm.11870. Access: abstract_metadata. Study: PMID40963295. 60. Osman AM, Toson B, Naik GR et al. A novel TASK channel antagonist nasal spray reduces sleep apnea severity in physiological responders: a randomized, blinded, trial. American journal of physiology. Heart and circulatory physiology. 2024. [PMID 38214905](https://pubmed.ncbi.nlm.nih.gov/38214905/). DOI: 10.1152/ajpheart.00541.2023. Access: abstract_metadata. Study: PMID38214905. 61. Foellner S, Guth P, Jorde I et al. Prevention of leakage due to mouth opening through applying an oral shield device (Sominpax™) during nasal CPAP therapy of patients with obstructive sleep apnea. Sleep medicine. 2020. [PMID 31884409](https://pubmed.ncbi.nlm.nih.gov/31884409/). DOI: 10.1016/j.sleep.2019.06.023. Access: abstract_metadata. Study: PMID31884409. 62. Koo SK, Park GH, Koh TK et al. Effect of mouth closure on upper airway obstruction in patients with obstructive sleep apnoea exhibiting mouth breathing: a drug-induced sleep endoscopy study. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery. 2020. [PMID 32162059](https://pubmed.ncbi.nlm.nih.gov/32162059/). DOI: 10.1007/s00405-020-05904-0. Access: abstract_metadata. Study: PMID32162059. ## Source-specific evidence cards ### [1] Influence of breathing route on upper airway lining liquid surface tension in humans. **Shows:** Randomized waking nasal versus oral breathing in eight healthy adults changes mucosal wetness and lining-liquid surface tension. **Does not show:** Wakefulness and surface-tension measures do not establish nocturnal AHI or functional improvement in OSA. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1. ### [2] Mandibular Advancement vs Combined Airway and Positional Therapy for Snoring: A Randomized Clinical Trial. **Shows:** Randomized primary-snoring study compares mandibular advancement with a nasal, positional and mouth-taping package; partner-rated response favors mandibular advancement. **Does not show:** Participants lacked OSA and the bundle does not isolate taping; 42 of 50 dyads completed and adverse-event withdrawals occurred in both groups. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3, SC4. ### [3] The Impact of Mouth-Taping in Mouth-Breathers with Mild Obstructive Sleep Apnea: A Preliminary Study. **Shows:** Twenty mild-OSA mouth breathers have lower median home-test AHI after one week of tolerated taping, from 8.3 to 4.7 events per hour. **Does not show:** Uncontrolled before-after order, tolerance selection, single-night variability and outcome-defined snoring responders preclude a controlled clinical crossing or general safety claim. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:2. Methods:paragraph 0, 1:2. Methods:paragraph 1, 1:2. Methods:paragraph 2, 1:2. Methods:paragraph 3, 1:2. Methods:paragraph 4, 1:2. Methods:paragraph 5, 1:2. Methods:paragraph 6, 2:3. Results:paragraph 0, 2:3. Results:paragraph 1, 2:3. Results:paragraph 2. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3, SC4. ### [4] Mouth puffing phenomena of patients with obstructive sleep apnea when mouth-taped: device's efficacy confirmed with physical video observation. **Shows:** Ten PSG participants provide video-confirmed detector signals of mouth puffing when taped, associated with OSA indices. **Does not show:** Detector validity is not treatment efficacy; abstract subgroup percentages are difficult to reconcile with its qualitative severity statement and require body verification before numeric use. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4. ### [5] Mouth Puffing Phenomenon and Upper Airway Features May Be Used to Predict the Severity of Obstructive Sleep Apnea. **Shows:** Seventy-one participants undergo usual then taped home nights; about half lack ODI improvement and intermittent puffing correlates with severity and airway narrowing. **Does not show:** Fixed night order and outcome-defined improved groups cannot identify causal responders prospectively or demonstrate controlled AHI benefit. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4. ### [6] Effect of mouth leak on effectiveness of nasal bilevel ventilatory assistance and sleep architecture. **Shows:** Random-order paired nights in nine long-term nasal bilevel ventilation users show less leak, lower carbon dioxide and arousals, and more REM with mouth sealing. **Does not show:** A ventilation adjunct in predominantly hypercapnic patients does not establish tape-alone OSA treatment or sustained daytime function. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3. ### [7] Mouth closing device (chinstrap) reduces mouth leak during nasal CPAP. **Shows:** Random-order nights in 15 CPAP users show a chinstrap reduces mouth leak and arousals while increasing snoring time. **Does not show:** Chinstrap is not tape alone; residual disturbance remains high and worsening respiratory disturbance in rare cases limits blanket safety claims. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4. ### [8] Mouth Closure and Airflow in Patients With Obstructive Sleep Apnea: A Nonrandomized Clinical Trial. **Shows:** Alternating-breath closure during drug-induced sleep endoscopy in 54 analyzed patients improves flow in moderate oral breathers but worsens it in high oral breathers and velopharyngeal obstruction. **Does not show:** Sedated flow is not natural-sleep AHI or a tape trial; twelve excluded baseline-flow recordings and obstruction-dependent effects limit generalization. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4. ### [9] Expiratory Velopharyngeal Obstruction: Sleep Endoscopy-Guided Treatment Strategies to Prevent Oral Breathing During Sleep. **Shows:** Sleep-endoscopy case series in 72 OSA patients observes more expiratory velopharyngeal obstruction during mouth closure or intraoral negative pressure than oral-appliance maneuvers. **Does not show:** Sedated maneuvers and nonrandomized comparisons do not establish tape-alone natural-sleep benefit; expiratory obstruction is a plausible baseline boundary. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4. ### [10] Inspiratory effort sensation to added resistive loading in patients with obstructive sleep apnea. **Shows:** Seventeen OSA patients have reduced waking inspiratory-load sensation compared with ten controls, which increases after two weeks of nasal CPAP. **Does not show:** Uncontrolled treatment and waking sensations cannot isolate tape effects or prove daytime functional recovery. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3. ### [11] Nasal obstruction and palate-tongue position on sleep-disordered breathing. **Shows:** In 275 suspected sleep-disordered breathing patients, Mallampati score correlates with PSG severity primarily among those reporting nasal obstruction. **Does not show:** Cross-sectional subgroup correlation is neither a validated tape-response classifier nor causal efficacy. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4. ### [12] Effect of treating severe nasal obstruction on the severity of obstructive sleep apnoea. **Shows:** Randomized sham-controlled crossover in ten nasal-obstructed OSA patients reduces nasal resistance, oral ventilation and AHI modestly with decongestant and dilator treatment. **Does not show:** The manipulated nasal obstruction provides an alternative mechanism; this is not a tape-alone trial and residual OSA persists. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4. ### [13] Obstructive sleep apnoea and oral breathing in patients free of nasal obstruction. **Shows:** OSA patients among 41 snorers with normal nasal resistance spend more sleep breathing orally, with AHI associated with oral breathing. **Does not show:** Normal nasal patency does not remove velopharyngeal or other obstruction; association does not establish that sealing prevents apnea. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4. ### [14] Partitioning of inhaled ventilation between the nasal and oral routes during sleep in normal subjects. **Shows:** Ten healthy adults have a small oral fraction of ventilation with no significant sleep-stage differences. **Does not show:** Normal-subject physiology is a baseline comparator, not a tape-treatment effect in OSA. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4. ### [15] Dynamic behaviour of the soft palate during nasal positive pressure ventilation under anaesthesia and paralysis: comparison between patients with and without obstructive sleep-disordered breathing. **Shows:** During anesthetized nasal positive-pressure ventilation, expiratory retropalatal closure is more frequent in sleep-disordered breathing patients than controls. **Does not show:** Anesthesia, paralysis, mouth closure and positive pressure jointly change physiology; the experiment does not establish natural-sleep taping benefit. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4. ### [16] Palatal prolapse as a signature of expiratory flow limitation and inspiratory palatal collapse in patients with obstructive sleep apnoea. **Shows:** Natural-sleep endoscopy in 22 OSA patients links expiratory palatal prolapse to flow limitation and predicts isolated palatal collapse. **Does not show:** Prediction of an obstruction phenotype does not demonstrate that taping treats it or that the derived classifier generalizes independently. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4. ### [17] Fast-computed tomographic evaluation of the effect of route of breathing on upper airway size and function in normal men. **Shows:** Waking CT in 30 normal men shows oral breathing narrows retropalatal dimensions while increasing minimum orohypopharyngeal area and genioglossus activity. **Does not show:** Regional compensations contradict a simple whole-airway narrowing narrative; waking anatomy is not tape-alone natural-sleep efficacy. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1. ### [18] Quality of life, compliance, sleep and nasopharyngeal side effects during CPAP therapy with and without controlled heated humidification. **Shows:** Randomized CPAP humidification study in 44 patients reduces dryness but does not improve sleep parameters, quality of life or compliance. **Does not show:** An alternative dryness treatment demonstrates symptom-function separation; it does not test tape-alone sleep apnea efficacy. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4. ### [19] Evaluation of craniofacial morphology in patients with obstructive sleep apnea using lateral cephalometry and dynamic MRI. **Shows:** Ten OSA patients show different skeletal and soft-tissue morphology according to dynamic MRI obstruction site. **Does not show:** Small descriptive anatomy does not validate taping-response prediction or establish treatment mechanism. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4. ### [20] Therapeutic Efficacy of Twin-Block and Fixed Oral Appliances in Patients with Obstructive Sleep Apnea Syndrome. **Shows:** Different-calendar cohorts using fixed closed-mouth versus twin-block advancement appliances have improved AHI, with larger reductions in the fixed-appliance group. **Does not show:** Nonrandomized cohorts and differing appliance geometry conflate mouth closure with mandibular advancement and do not isolate tape. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4. ### [21] Obstructive sleep apnea treatment with a twopiece mandibular advancement device with an elastic retention band in combination with orofacial myofunctional therapy: a case report. **Shows:** A severe-OSA case improves with an elastic-retained mandibular appliance and orofacial training after inadequate prior appliance response. **Does not show:** Single case and multicomponent treatment cannot identify the contribution of lip closure or demonstrate general tape efficacy. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3. ### [22] A Validation of Six Wearable Devices for Estimating Sleep, Heart Rate and Heart Rate Variability in Healthy Adults. **Shows:** PSG comparison in 53 healthy adults shows high sleep-wake agreement but materially lower stage agreement across six wearable generations. **Does not show:** Methodological evidence belongs to the sleep-score appendix; device validation is not a causal clinical intervention or universal failure of all trackers. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4. ### [23] Performance of seven consumer sleep-tracking devices compared with polysomnography. **Shows:** Three-night PSG testing of seven consumer trackers in 34 healthy adults finds high sleep sensitivity, limited wake specificity and inconsistent stages, worse during disrupted sleep. **Does not show:** Device- and setting-specific validation cannot validate an AHI treatment response or be generalized to newer generations without direct testing. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4. ### [24] Accuracy of Three Commercial Wearable Devices for Sleep Tracking in Healthy Adults. **Shows:** Thirty-five healthy adults provide one-night PSG validation of Oura Gen 3, Fitbit Sense 2 and Apple 8; sleep sensitivity is high and stage biases differ by device. **Does not show:** Healthy single-night testing does not establish OSA diagnosis or treatment tracking; findings do not support a blanket claim that trackers measure nothing useful. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4. ### [25] Accuracy of 11 Wearable, Nearable, and Airable Consumer Sleep Trackers: Prospective Multicenter Validation Study. **Shows:** Two-center PSG comparison of eleven trackers in 75 participants finds substantial device, stage and baseline-severity variation. **Does not show:** Large epoch counts are not independent participants; wellness-stage estimation does not validate tape-treatment AHI endpoints. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4. ### [26] A performance validation of six commercial wrist-worn wearable sleep-tracking devices for sleep stage scoring compared to polysomnography. **Shows:** Sixty-two adults provide PSG comparisons of six wearables, with high sleep sensitivity but low wake specificity and fair-to-moderate kappa. **Does not show:** One-night and device-generation specificity limit individual clinical interpretation; this is methodological evidence rather than treatment efficacy. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4. ### [27] AI-Driven sleep staging from actigraphy and heart rate. **Shows:** Actigraphy and heart-rate sleep-staging model validates in MESA and MrOS with useful aggregate stage-duration estimates and a separate watch dataset. **Does not show:** Algorithm validation and averaged stage duration do not establish consumer device diagnosis or a causal sleep-health intervention. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4. ### [28] A consumer wearable device for tracking sleep respiratory events. **Shows:** In twenty high-OSA-risk adults, a wearable underestimates AHI versus cardiorespiratory monitoring and the AHI correlation is weak. **Does not show:** Small device-specific diagnostic validation cannot justify clinical treatment tracking or general failure of every wearable. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4. ### [29] Validity and clinical utility of a wrist-worn device against polysomnography. **Shows:** Ninety-eight sleep-clinic patients show high watch sleep sensitivity with systematic duration and wake biases, less satisfactory agreement in OSA and insomnia. **Does not show:** Clinical-subgroup bias matters for individual response measurement; no sleep intervention was tested. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4. ### [30] A computationally efficient algorithm for wearable sleep staging in clinical populations. **Shows:** A cardiac and movement neural classifier achieves useful held-out PSG stage agreement with substantially faster computation than an HRV-feature approach. **Does not show:** Held-out classifier performance is not a randomized clinical benefit or universal validation of consumer sleep scores. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4. ### [31] Multinight Prevalence, Variability, and Diagnostic Misclassification of Obstructive Sleep Apnea. **Shows:** Large selected under-mattress-user dataset shows substantial night-to-night AHI variation and lower classification error with multiple nights. **Does not show:** Purchaser selection and proprietary measurement limit prevalence generalization, but variability is a concrete confounder for fixed-order single-night tape pilots. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4. ### [32] Validating a Consumer Smartwatch for Nocturnal Respiratory Rate Measurements in Sleep Monitoring. **Shows:** PSG testing in 195 clinic participants finds watch respiratory-rate agreement poorer in severe OSA than normal-to-moderate groups. **Does not show:** Respiratory-rate accuracy is distinct from apnea detection, sleep staging and treatment benefit. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4. ### [33] Consumer-grade sleep trackers are still not up to par compared to polysomnography. **Shows:** Prospective PSG comparisons of multiple applications and wearables find poor absolute staging validity with some relative pattern utility. **Does not show:** Applications, devices and enrollment dates differ; the result does not establish a universal contemporary-device ceiling or clinical treatment effect. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4. ### [34] A validation study of Fitbit Charge 2™ compared with polysomnography in adults. **Shows:** Fitbit Charge 2 PSG validation in 44 adults finds high sleep sensitivity with deep-sleep underestimation and distinct stage biases. **Does not show:** Single-night healthy screening and algorithm generation limit OSA interpretation; sleep sensitivity is not clinical diagnostic specificity. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4. ### [35] Sleep Apnea Severity Estimation from Respiratory Related Movements Using Deep Learning. **Shows:** Tracheal accelerometry predicts PSG AHI in twenty participants using three-fold cross-validation. **Does not show:** Small internal validation and correlation do not establish independent diagnostic accuracy or treatment-response validity. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4. ### [36] Morphic Sensors for Respiratory Parameters Estimation: Validation against Overnight Polysomnography. **Shows:** Morphic t-shirt sensors capture respiratory rate and chest/abdominal motion against PSG in 32 volunteers. **Does not show:** Respiratory-motion agreement does not establish AHI diagnosis, cortical sleep stages or causal health benefit. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4. ### [37] A validation study of the WHOOP strap against polysomnography to assess sleep. **Shows:** WHOOP testing across 86 sleeps in twelve healthy adults finds reasonable sleep-wake agreement with weaker four-stage categorization. **Does not show:** Researchers entered bedtimes and repeated sleeps share participants; performance does not validate unrestricted clinical use. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4. ### [38] The Promise of Sleep: A Multi-Sensor Approach for Accurate Sleep Stage Detection Using the Oura Ring. **Shows:** Ring multisensor model tested across 440 nights in 106 people improves staging when autonomic and circadian features are included. **Does not show:** Cross-validated development accuracy does not establish all proprietary deployed-device accuracy or therapeutic sleep improvement. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4. ### [39] Performance of wearable finger ring trackers for diagnostic sleep measurement in the clinical context. **Shows:** Three ring trackers show small group-average differences but substantial individual errors and weaker clinical sleep-stage agreement. **Does not show:** Group means conceal single-person uncertainty; clinical diagnosis and tape benefit cannot be inferred from a composite wellness score. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4. ### [40] Optimizing wearable single-channel electroencephalography sleep staging in a heterogeneous sleep-disordered population using transfer learning. **Shows:** Transfer-learned single-channel EEG stages 52 sleep-disordered recordings with strong PSG agreement. **Does not show:** An EEG headband and training pipeline differ from wrist motion/PPG; this supports technology-specific validation rather than a universal wearable failure claim. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4. ### [41] Mandibular advancement device therapy in patients with epiglottic collapse. **Shows:** Matched observational OSA groups with and without epiglottic collapse show similar ODI improvement using mandibular advancement. **Does not show:** Absence of a significant interaction does not establish equivalence; a mandibular device is not tape alone. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4. ### [42] Effect of 10-minute oropharyngeal exercise on the apnoea-hypopnoea index. **Shows:** Single-arm oropharyngeal exercise study shows modest AHI improvement in a baseline severity group after twelve weeks. **Does not show:** No concurrent control and outcome-defined improved groups limit age-response claims; strengthening is distinct from external tape closure. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3. ### [43] Response of genioglossus muscle activity to nasal airway occlusion in normal sleeping adults. **Shows:** Nasal occlusion during sleep in twelve healthy men elicits respiratory effort and stage-dependent arousal or oral breathing. **Does not show:** Experimental obstruction physiology shows compensatory pathways, without testing long-term taping efficacy or safety. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4. ### [44] Pressure-volume behavior of the upper airway. **Shows:** Isolated upper-airway force-volume experiments in eleven anesthetized dogs relate muscle respiratory efforts to airway expansion. **Does not show:** Surgical isolation, anesthesia and species differences prevent inference about natural-sleep mouth taping in humans. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1. ### [45] Relationships between Lip Seal Strength, Tongue Pressure, and Daytime Sleepiness in Japanese Workers: A Cross-Sectional Study. **Shows:** Cross-sectional Japanese-worker data associate weaker lip seal with greater reported sleepiness after age and BMI adjustment. **Does not show:** Lip strength may be a marker or consequence; no intervention demonstrates sleepiness prevention. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3. ### [46] Assessment of the performance of nasal pillows at high CPAP pressures. **Shows:** Randomized nasal-pillow versus nasal-mask CPAP crossover in 21 people finds no significant objective AHI, leak or usage differences. **Does not show:** Nonsignificance is not prespecified equivalence and does not test tape monotherapy; interface preference differs. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4. ### [47] The impact of V̇-Com on chinstrap usage and study completion rates during CPAP titration. **Shows:** Retrospective CPAP titration series associates a circuit-resistance device with less chinstrap use and fewer aborted studies. **Does not show:** No randomized device control and modeled hypothetical placebo responses preclude causal effect estimates or tape efficacy. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4. ### [48] The key role of the mandible in modulating airflow amplitude during sleep. **Shows:** PSG fragments in 25 OSA patients link mandibular movement and masseter activity to airflow changes around arousals. **Does not show:** Within-person temporal associations and arousal do not isolate closure as the cause of sustained AHI benefit. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1. ### [49] Targeted Hypoglossal Nerve Stimulation for Patients With Obstructive Sleep Apnea: A Randomized Clinical Trial. **Shows:** Randomized targeted hypoglossal stimulation improves objective AHI and patient-reported outcomes versus control in 138 participants, with procedure-related adverse events. **Does not show:** This establishes an alternative neuromuscular treatment, not tape efficacy; attached correction PMID38512282 must remain linked and its unread details limit numeric interpretation. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID38512282. Subclaims: SC2, SC3, SC4. ### [50] Endotypic Mechanisms of Successful Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea. **Shows:** Secondary STAR-trial analysis associates baseline loop gain, arousal threshold and compensation with hypoglossal stimulation response. **Does not show:** A post hoc response predictor and incomplete baseline recordings do not validate prospective tape selection or demonstrate mediator necessity. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4. ### [51] Association of hypoglossal nerve stimulator response with machine learning identified negative effort dependence patterns. **Shows:** Machine-learned nasal-flow pattern analysis associates baseline negative-effort dependence with stimulation response in 41 analyzable patients. **Does not show:** Small retrospective prediction is not independent prospective validation or a taping intervention. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4. ### [52] Comparison of nasal and face mask ventilation in anaesthetised obese adults: A randomised controlled study. **Shows:** Randomized anesthetized mask-ventilation comparison in ninety adults reduces leak and airway pressures with a nasal mask without significant tidal-volume advantage. **Does not show:** Anesthesia induction and positive pressure differ from natural-sleep tape use; nonsignificant volume difference is not proof of equivalence. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4. ### [53] Feasibility of a self-setting CPAP machine. **Shows:** Early auto-CPAP feasibility study identifies severe mouth leak as a source of inappropriate pressure prescription and successful obstruction control in most patients. **Does not show:** Device algorithm feasibility and leak mechanisms do not establish tape-alone OSA treatment or modern clinical performance. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4. ### [54] The Efficacy of Low-Level Continuous Positive Airway Pressure for the Treatment of Snoring. **Shows:** Reversal crossover in primary snorers shows pressure-dependent snoring reduction with low-level nasal CPAP. **Does not show:** Baseline significant OSA and daytime sleepiness were excluded; controlled snoring is distinct from taping, apnea treatment and daytime function. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3. ### [55] Comparison of expiratory pressures generated by four different EPAP devices in a laboratory bench setting. **Shows:** Bench testing finds materially different expiratory pressure profiles across four EPAP products. **Does not show:** Device clearance and measured resistance do not establish equivalent clinical efficacy, tolerance or safety, and the devices differ from tape. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4. ### [56] Oral appliance influence on jaw function in obstructive sleep apnea. **Shows:** Oral-appliance follow-up in 192 of 302 assigned patients finds stable measured jaw function but more perceived morning opening/chewing and occlusal changes. **Does not show:** Per-protocol attrition and a different treatment limit inference about tape safety; no blanket absence-of-harm conclusion is justified. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4. ### [57] Randomized Trial of 2 Self-Titrated Oral Appliances for Airway Management. **Shows:** Randomized crossover compares mandibular devices allowing or restricting mouth opening, with similar respiratory-event improvement among completers. **Does not show:** Advancement geometry, attrition and repeated treatment periods prevent isolating tape-like closure; mouth restriction is not shown superior. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4. ### [58] Novel porous oral patches for patients with mild obstructive sleep apnea and mouth breathing: a pilot study. **Shows:** Thirty mild-OSA open-mouth breathers have lower median PSG AHI and sleepiness during porous-patch use than baseline. **Does not show:** Uncontrolled before-during assessment and a distinct patch formulation do not establish a credible controlled taping effect or necessity of the anatomical mediator. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3. ### [59] The role of mouth tape for CPAP use in patients with mouth breathing and OSA. **Shows:** Randomized crossover in 62 CPAP-treated OSA patients shows more device usage and improved symptom measures when tape is added, with adverse effects reported. **Does not show:** The positive controlled result is CPAP adjunct adherence, not tape-alone AHI reduction; actual full-body safety details were not accessed here. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3, SC4. ### [60] A novel TASK channel antagonist nasal spray reduces sleep apnea severity in physiological responders: a randomized, blinded, trial. **Shows:** Random-order nasal-antagonist trial in ten OSA patients finds no systematic whole-cohort AHI change; the nasal-only closure-plus-drug arm is not superior. **Does not show:** Drug and closure are bundled, baseline physiologic selection limits scope, and positive unrestricted-drug subgroup results do not establish tape efficacy. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4. ### [61] Prevention of leakage due to mouth opening through applying an oral shield device (Sominpax™) during nasal CPAP therapy of patients with obstructive sleep apnea. **Shows:** Randomized mask-interface comparison in 29 CPAP users finds no significant objective difference between nasal mask alone and nasal mask with an oral shield. **Does not show:** An oral shield is a CPAP adjunct, not tape alone; lack of significance is not proof of equivalence or no effect at all. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4. ### [62] Effect of mouth closure on upper airway obstruction in patients with obstructive sleep apnoea exhibiting mouth breathing: a drug-induced sleep endoscopy study. **Shows:** Sleep-endoscopy study in eighteen OSA patients finds improved obstruction areas in some mouths-closed maneuvers and classifies response after the maneuver. **Does not show:** Sedated anatomy and post-result responders cannot establish natural-sleep clinical improvement; abstract significance wording is internally inconsistent. **Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.